Omeprazole-group of drugs called proton pump inhibitors

Omeprazole is used to reduce stomach acid across India. Learn more about the side effects, uses and dosage information for omeprazole at Patient.

Omeprazole-group of drugs called proton pump inhibitors

Omeprazole; Losec; Prilosec; Antra; Omeprazon

Abcid, Acichek, Acidof, Acigone, Aciom, Acitec, Acitec, Acizole, Acraz, Adprazole, Adzole, Aig, Alticer, Amaze, Amnzole, Apoxd, Atozol, Aurizol-O, Avizol, Awnacid, Axefire, Azinorm-O, Azol-20, Binacid, Bio-Omeprazole, Biocid, Biomac, Bisid, Blancid, Brocid, Burnil, C-Praz, Capcid, Capocid, Cg Mez, Cgmag, Cinom, Coromez, Coszol, Coz, Coz-M, Cozep, Cucid, Cuzole, Datzol, DGR, Diocid, Dorcan, Drag-20, Duotac

6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole

Oral absorption, 95% protein binding, hepatic metabolism and excreted via urine.

Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H⁺/K⁺-ATPase in the gastric parietal cell. This acts specifically on the proton pump, blocks the final step in acid production, thus reducing gastric acidity.

20 mg daily oral. 

Indicated for the treatment of duodenal ulcers, benign gastric ulcers, gastroesophageal reflux disease (GERD), heartburn and other symptoms associated with GERD, erosive esophagitis, and long-term treatment of pathological hypersecretory conditions like multiple endocrine adenomas, Zollinger-Ellison syndrome, and systemic mastocytosis.

Diarrhoea, nausea, fatigue, constipation, vomiting, flatulence, acid regurgitation, taste perversion, arthralgia, myalgia, urticaria, dry mouth, dizziness, headache, paraesthesia, abdominal pain, skin rashes, weakness, back pain, upper respiratory infection, cough.

• Absorption may be delayed.
• Decreases absorption of dasatinib, itraconazole, ketoconazole, oral iron salts.
• St John's wort decreases omeprazole levels.
• Decreases levels of nelfinavir.
• Avoid ethanol
• Increases levels of benzodiazepines (e.g. diazepam, midazolam, triazolam), HMG-CoA reductase inhibitor, CYP2C19 substrates (e.g. methsuximide, citalopram, propranolol, diazepam, sertraline and phenytoin), and CYP2C9 substrates (e.g. bosentan, dapsone, fluoxetine, glimepiride, glipizide, losartan, montelukast, nateglinide, paclitaxel, phenytoin, warfarin, and zafirlukast).
•  Enhances the adverse/toxic effect of cilostazol.
• Decreased levels/effects with CYP2C19 inducers (e.g. aminoglutethimide, carbamazepine, phenytoin, and rifampin).
• Decreases excretion of methotrexate.
• Avoid concurrent use with clopidogrel.

 May alter the concentrations/effects of clozapine.

Hypersensitivity.

Store at 15-30 °C.

Molecular weight

345.416

Molecular formula

C17H19N3O3S

CAS number

73590-58-6

Precautions

Exclude malignancy, prolonged use, and hepatic impairment. Pregnancy, lactation, children <1 year. Elderly and Asians